Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Elon Musk
Donald Trump
Artificial Intelligence
Social Media
Tesla
Regulation
World Cup
Stock Markets
European Union
Property
Baseball
Published • loading... • Updated

Radium-223 Safety and Efficacy Sustained in 7-Year Real-World Update

Summary by targetedonc.com
Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall survival.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
auntminnie.comauntminnie.com

Radium-223 safety confirmed in long-term study

At ASCO 2025, researchers shared data on the long-term safety of Ra-223 treatments for metastatic castration-resistant prostate cancer.

Read Full Article
targetedonc.comtargetedonc.com

Radium-223 Safety and Efficacy Sustained in 7-Year Real-World Update

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall survival.

Read Full Article
urologytimes.comurologytimes.com

Long-term data support radium-223 safety in mCRPC

“Prior taxanes did not increase reported hematological adverse events during treatment with Ra-223,” the investigators reported.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

urologytimes.com broke the news in on Monday, June 2, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal